We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
The investment strategy Now Pensions implemented in Q1 2024 has enabled the master trust to be “on track” to achieve net zero by 2050 and a 50 per cent reduction by 2030, based on 2019 levels ...